CDKN2A and central nervous system cancer: Recurrent loss or other inactivation of PTPRD has been detected in different human malignancies16–21, and one-copy loss of PTPRD has also been oncogenic in p16Ink4a knockout RCAS PDGFB/Nestin-tvA glioma mouse model16.